Compared with the use of other migraine medications, use of erenumab did not increase cardiovascular or cerebrovascular risks.

The new guidelines for the use of monoclonal antibodies (mAbs) published in Neurodegenerative Diseases, serve as exemplary clinical recommendations for clinicians and healthcare providers, supporting ...

Cheyney, PA, May, 5 2025 - Navrogen, Inc., a biopharmaceutical company specialized in developing antibody-based therapies for ...

Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ETCompany ParticipantsSteve Frank - Vice President of Investor ...

The following is a summary of “Lipid Management in US Commercial and Medicare Enrollees with Atherosclerotic Cardiovascular ...

For many years, the potential of immunoglobulin M (IgM) antibodies was not fully understood because of characteristics different to the well-known immunoglobulin G type like low target affinity, cross ...

For example, a study published in the Journal of Medicinal Food found that participants taking a combination supplement containing acetic acid (found in ACV) experienced significant improvements in ...

Y-mAbs Therapeutics (NASDAQ:YMAB) lost ~6% on Tuesday after Bank of America downgraded the cancer drug developer to Underperform from Neutral, arguing that most of the market potential for the ...

Y-mAbs presented preclinical PK data for CD38-SADA at the 2025 AACR Annual Meeting, supporting its cancer treatment development. Y-mAbs Therapeutics, Inc. announced the presentation of preclinical ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Y-mAbs Therapeutics, Inc. (YMAB) reports results for the quarter ended March 2025. While this widely-known consensus ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...